These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37771841)

  • 1. The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe.
    Nicholas R; Rodgers J; Witts J; Lerede A; Friede T; Hillert J; Forsberg L; Glaser A; Manouchehrinia A; Ramanujam R; Spelman T; Klyve P; Drahota J; Horakova D; Joensen H; Pontieri L; Magyari M; Ellenberger D; Stahmann A; Butzkueven H; Van Der Walt A; Bezlyak V; Lines C; Middleton R
    Ther Adv Neurol Disord; 2023; 16():17562864231198963. PubMed ID: 37771841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
    Forsberg L; Spelman T; Klyve P; Manouchehrinia A; Ramanujam R; Mouresan E; Drahota J; Horakova D; Joensen H; Pontieri L; Magyari M; Ellenberger D; Stahmann A; Rodgers J; Witts J; Middleton R; Nicholas R; Bezlyak V; Adlard N; Hach T; Lines C; Vukusic S; Soilu-Hänninen M; van der Walt A; Butzkueven H; Iaffaldano P; Trojano M; Glaser A; Hillert J;
    Mult Scler J Exp Transl Clin; 2023; 9(1):20552173231153557. PubMed ID: 36816812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
    Duddy M; Wilkinson C; Medhurst S; Rhys K
    Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study.
    Deri N; Barboza A; Vrech C; Rey R; Burgos M; Fiol M; CalvoVildoso C; Patrucco L; Jose G; Aliberti P; Chirico D; Federico MB; Seifer G; Piedrabuena R
    Mult Scler Relat Disord; 2024 Mar; 83():105421. PubMed ID: 38244525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
    Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
    Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
    Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
    Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.
    Braune S; Rossnagel F; Dikow H; Bergmann A;
    BMJ Open; 2021 Aug; 11(8):e042480. PubMed ID: 34344670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
    Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
    JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
    Perrone V; Veronesi C; Giacomini E; Citraro R; Dell'Orco S; Lena F; Paciello A; Resta AM; Nica M; Ritrovato D; Degli Esposti L
    Clin Epidemiol; 2022; 14():1327-1337. PubMed ID: 36387930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression.
    Barcutean L; Maier S; Bajko Z; Stoian A; Mosora O; Sarmasan E; Manescu IB; Balasa R
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542037
    [No Abstract]   [Full Text] [Related]  

  • 19. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
    Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
    J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey.
    Gross HJ; Watson C
    Neuropsychiatr Dis Treat; 2017; 13():1349-1357. PubMed ID: 28572730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.